Michael B. Atkins, Md, Regarding The Long-Term Follow Up Of Checkmate-004 In Metastatic Melanoma

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

Michael B. Atkins, MD: New Therapies and New Questions for Metastatic Melanoma

Vital Options International

Dr. Michael Atkins on Immunotherapy or Targeted Therapy as First Treatment for Advanced Melanoma

Michael Atkins, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in RCC patients

Dr. Atkins on Long-Term Outcomes of the CheckMate 204 Trial in Melanoma

Melanoma & Immunotherapy: Ask Dr. Michael Atkins

MedStar Georgetown University Hospital

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in Melanoma

Dr. Hodi on Long-Term Follow-Up of Nivolumab in Patients With Melanoma

Dr. Atkins on Adjuvant Ipilimumab in Melanoma

Michael Atkins, MD, on follow up investigation of Checkmate 025 in renal cell carcinoma patients

Explaining Therapeutic Options to Patients With Advanced Melanoma

Longterm Benefits from Nivolumab and Ipilimumab Combination Therapy

Specialty Pharmacy Times

Michael B. Atkins, MD, comments on clinical trials investigating the use of I-O and TKIs in RCC

Specific Patient Populations Benefit from Nivolumab/Ipilimumab Combo Therapy

Specialty Pharmacy Times

Michael B. Atkins, MD, on the role of IMDC classification in treatment decision-making

Dr. Michael Atkins on Benefits of Adjuvant Treatment in Melanoma

Targeted Oncology

Metastatic melanoma: the CheckMate 067 and 069 trials

New Targets, New Pathways Michael B. Atkins, M.D.